CYTOMX THERAPEUTICS INC (CTMX) Stock Price & Overview
NASDAQ:CTMX • US23284F1057
Current stock price
The current stock price of CTMX is 4.4 USD. Today CTMX is down by -19.27%. In the past month the price decreased by -18.67%. In the past year, price increased by 559.87%.
CTMX Key Statistics
- Market Cap
- 745.536M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
CTMX Stock Performance
CTMX Stock Chart
CTMX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CTMX. When comparing the yearly performance of all stocks, CTMX is one of the better performing stocks in the market, outperforming 99.38% of all stocks.
CTMX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CTMX. CTMX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
CTMX Earnings
On March 16, 2026 CTMX reported an EPS of -0.22 and a revenue of 660.00K. The company missed EPS expectations (-130.26% surprise) and missed revenue expectations (-91.81% surprise).
CTMX Forecast & Estimates
15 analysts have analysed CTMX and the average price target is 9.44 USD. This implies a price increase of 114.43% is expected in the next year compared to the current price of 4.4.
For the next year, analysts expect an EPS growth of -854.5% and a revenue growth -62.57% for CTMX
CTMX Groups
Sector & Classification
CTMX Financial Highlights
Over the last trailing twelve months CTMX reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -110.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.66% | ||
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| Debt/Equity | 0 |
CTMX Ownership
CTMX Latest News, Press Relases and Analysis
CTMX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 388.573B | ||
| AMGN | AMGEN INC | 15.4 | 194.674B | ||
| GILD | GILEAD SCIENCES INC | 15.98 | 179.261B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 117.486B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 80.247B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.19 | 42.494B | ||
| INSM | INSMED INC | N/A | 31.024B | ||
| NTRA | NATERA INC | N/A | 28.116B | ||
| BIIB | BIOGEN INC | 11.34 | 27.193B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.76 | 23.669B | ||
| MRNA | MODERNA INC | N/A | 21.299B | ||
| EXAS | EXACT SCIENCES CORP | 341.33 | 19.841B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTMX
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Company Info
IPO: 2015-10-08
CYTOMX THERAPEUTICS INC
151 Oyster Point Blvd., Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Sean A. McCarthy
Employees: 119
Phone: 16505153185
CYTOMX THERAPEUTICS INC / CTMX FAQ
What does CTMX do?
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
What is the current price of CTMX stock?
The current stock price of CTMX is 4.4 USD. The price decreased by -19.27% in the last trading session.
Does CTMX stock pay dividends?
CTMX does not pay a dividend.
What is the ChartMill rating of CYTOMX THERAPEUTICS INC stock?
CTMX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is CYTOMX THERAPEUTICS INC (CTMX) stock traded?
CTMX stock is listed on the Nasdaq exchange.
Should I buy CTMX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTMX.